drugset / Trial / NCT03496519
Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A phase 1 study examining the combination of Durvalumab (MEDI4736) and Trabectedin in various solid tumor types. The study seeks to determine a safe dose of the combination of study drugs and then examine this dose in larger groups of patients of specific tumor types to evaluate its anti-tumor efficacy. Treatment will continue in patients who respond for up to 1 year.
Timeline
- Start
- 2018-10-01
- Primary completion
- 2021-10-31
- Completion
- 2021-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1125 mg | Intravenous |
| Subject | Trabectedin | Small molecule | 0.5 mg/m2 | Intravenous |
| Subject | Trabectedin | Small molecule | 0.75 mg/m2 | Intravenous |
| Subject | Trabectedin | Small molecule | 1 mg/m2 | Intravenous |
| Subject | Trabectedin | Small molecule | 1.2 mg/m2 | Intravenous |
| Subject | Trabectedin | Small molecule | 1.5 mg/m2 | Intravenous |